399 related articles for article (PubMed ID: 23333219)
1. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M; Bonkovsky HL; Kum C; Davern T; Hayashi PH; Kleiner DE; Serrano J; Rochon J; Fontana RJ; Bonacini M;
Clin Gastroenterol Hepatol; 2013 May; 11(5):558-564.e3. PubMed ID: 23333219
[TBL] [Abstract][Full Text] [Related]
2. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
Björnsson ES; Gunnarsson BI; Gröndal G; Jonasson JG; Einarsdottir R; Ludviksson BR; Gudbjörnsson B; Olafsson S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):602-8. PubMed ID: 25131534
[TBL] [Abstract][Full Text] [Related]
3. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
6. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
8. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children.
Ricciuto A; Kamath BM; Walters TD; Frost K; Carman N; Church PC; Ling SC; Griffiths AM
J Pediatr; 2018 Mar; 194():128-135.e1. PubMed ID: 29274889
[TBL] [Abstract][Full Text] [Related]
9. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
[No Abstract] [Full Text] [Related]
11. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
[TBL] [Abstract][Full Text] [Related]
12. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.
Pontikaki I; Shahi E; Frasin LA; Gianotti R; Gelmetti C; Gerloni V; Meroni PL
Clin Rev Allergy Immunol; 2012 Apr; 42(2):131-4. PubMed ID: 21403999
[TBL] [Abstract][Full Text] [Related]
13. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
[TBL] [Abstract][Full Text] [Related]
14. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
15. Liver toxicity of TNFalpha antagonists.
Dominique L
Joint Bone Spine; 2008 Dec; 75(6):636-8. PubMed ID: 18952478
[No Abstract] [Full Text] [Related]
16. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
17. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
19. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
[TBL] [Abstract][Full Text] [Related]
20. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
